More

    Warning: Illegal string offset 'sidebar' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 498

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 498

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 500

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 504

    Warning: Illegal string offset 'sidebar' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 516

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 516

    Warning: Illegal string offset 'home' in /home/customer/www/stocks.com.au/public_html/wp-content/themes/mining/functions.php on line 518

    Microba Life Sciences executes agreement with SYNLAB International to distribute testing technology into Italy and Portugal

    Microbiome company Microba Life Sciences (ASX:MAP) reports it has executed an agreement with medical diagnostic services company SYNLAB International affiliate organisations Synlab Italia and SYNLABHEALTH to distribute Microba’s testing technology into Italy and Portugal.

    The company says it entered into a master agreement with SYNLAB International in 2020, and an agreement with SYNLAB Diagnosticos Globales to deliver its testing to healthcare providers in Spain, with the option to formalise distribution agreements across their affiliate organisations which operate in 36 countries.

    With positive sales and customber feedback in Spain, SYNLAB further activated their rights through an amendment to the master agreement with Microba in October to pursue formal expansion into additional countries across Europe and Latin America.

    Italy represents a major market for gut health and the microbiome, and we are excited to get our testing into the hands of clinicians and patients across these 2 regions”

    Microba Senior Vice President of Services Bernie Woodcroft says: “I am pleased by our recent progress in distribution expansion with SYNLAB, Europe’s largest medical diagnostic company.

    Italy represents a major market for gut health and the microbiome, and we are excited to get our testing into the hands of clinicians and patients across these 2 regions.”

    Microba reports a first group of new agreements have now been signed with SYNBAL affiliate organisations Synlab Italia and SYNLABHEALTH for Italy and Portugal respectively.

    The agreement in Italy provides 2 years of exclusive distribution rights for healthcare providers, and the non-exclusive distribution rights out to 31 December 2028.

    The company says Italy is the third largest market in the world for probiotic sales, highlighting the awareness of gut health which makes it a key market for Microba’s microbiome testing.

    The agreement in Portugal provides non-exclusive distribution rights for healthcare providers out to 31 December 2028.

    Microba states entry into both Italy and Portugal represents another ‘positive’ advancement in distribution with Europe’s ‘largest’ medical diagnostics company, and more affiliate agreements are anticipated to be completed in the near term to continue this ‘rapid’ expansion activity with SYNLAB.

    Microba Life Sciences is a ‘precision’ microbiome company driven to improve human health. With ‘world-leading’ technology for measuring the human gut microbiome, the company is driving the discovery and development of novel therapeuticcs for ‘major’ chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.

    Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

    SYNLAB Group is the ‘leader’ in medical diagnostic services and specialty testing in Europe. The group offers a full range of ‘innovative’ and ‘reliable’ medical diagnostics to patients, practising doctors, hospitals, clinics, governments and corporations.

    The company operates in 36 countries across 4 continents and holds ‘leading’ positions in most markets, ‘regularly’ reinforcing the strength of its network through a ‘proven’ acquisition strategy.

    Harry Mulholland
    Harry Mulholland
    Hailing from the Central Coast region of NSW, Harry is a passionate journalist with a background in print, radio and ESG news. When not bashing away on his keyboard, he can be found brewing a coffee or playing with his dog.